CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...
Phase 3
London, London, City Of, United Kingdom and 113 other locations
with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...
Phase 3
London, United Kingdom and 155 other locations
and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...
Phase 2
London, United Kingdom and 42 other locations
The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as...
Phase 3
London, United Kingdom and 164 other locations
An open label single arm phase II trial in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma which is M...
Phase 2
Cambridge, Cambridgeshire, United Kingdom
first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
London, United Kingdom and 203 other locations
of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...
Phase 2, Phase 3
London, United Kingdom and 83 other locations
mCRPC. Patients enrolled in the Phase 2a portion of the study will have either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma...
Phase 1, Phase 2
London, Great Britain, United Kingdom and 11 other locations
The purpose of the study is to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of...
Phase 2
London, United Kingdom and 16 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
London, United Kingdom and 195 other locations
Clinical trials
Research sites
Resources
Legal